SHANGHAI -- China's Sinovac Biotech has raised more than $500 million from investors to help double production of its COVID-19 vaccine CoronaVac.
Hong Kong-listed Sino Biopharmaceutical, controlled by CP Pharmaceutical Group, is to put in $515 million, giving it a 15% stake in Sinovac Life Sciences, the unit in charge of CoronaVac production.
